Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-Risk Extremity Soft Tissue Sarcoma

Overview of attention for article published in ASCO Educational Book, May 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 1 news outlet

twitter: 16 X users

Readers on

mendeley: 32 Mendeley

So far, Altmetric has seen 19 X posts from 16 X users, with an upper bound of 63,330 followers.

@Monthy_A @AChargy @DrOrtizCruz @GrupoGeis @aredondo12 @belenbelinchon @SarcomasHULP @bstt_course https://t.co/d9QwhuQxIv sin duda la mayoría de las indicaciones hoy en día de tratamiento sistémico en estos pacientes es en neoadyuvancia y el punto de agre…

RT @JTrentMDPhD: Looking forward to additional evidence supporting Neoadjuvant and Adjuvant Chemotherapy for Soft-Tissue #Sarcoma ⁦@ctosoci…

Looking forward to additional evidence supporting Neoadjuvant and Adjuvant Chemotherapy for Soft-Tissue #Sarcoma ⁦@ctosociety⁩ ⁦Annual meeting. @SarcomaAlliance⁩ ⁦@CureSarcoma⁩ ⁦@ASCO⁩ https://t.co/gBDRIb0pkc

RT @DrOrtizCruz: We have to read this article: Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-Risk…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 15 additional X posts.